THROMBOPHILIC PANEL FACTOR II – FACTOR V – MTHFR (6 VARIANTS)
Why get tested?
The genetic test is indicated in: women who intend to take oral contraceptives; women with previous episodes of thrombosis during pregnancy or with a history of early (3 months) abortion; women who intend to undergo estrogen-progestogen replacement therapy. Furthermore, in all subjects with previous episodes of venous thromboembolism or arterial thrombosis or with a positive family history for these episodes.
What the test detects and what the variants cause
The test allows the genotyping of variants can be performed for selected variants or in the combination PT6 (hereditary thrombophilia 6 variants) which includes the 3 variants of Factor V, the variant of Factor II, and the 2 variants of the MTHFR gene. The genetic test allows to identify whether the subject is a carrier or not of one or more of one of the variants associated with hereditary thrombophilia and this allows to set up any preventive antithrombotic therapy, and to identify other family members at risk early.
How testing works
The genetic test consists in the execution of a blood sampling, in the extraction of genomic DNA and in the analysis of one or more of one of the aforementioned variants by sequencing or by means of a CE-IVD Thrombosis SNP Panel Assay kit based on the real-time PCR technique.
Results in 10 working days.
Sensitivity and specificity
Analytical sensitivity and specificity > 99,9%.